NASDAQ:XOMAXOMA Stock Price, Forecast & News

$21.70

-0.91 (-4.02 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$21.18

Now: $21.70▼

$23.12

50-Day Range

$19.30

MA: $22.45▼

$25.51

52-Week Range

$14.03

Now: $21.70▼

$28.85

Volume35,400 shs

Average Volume52,265 shs

Market Capitalization$239.03 million

P/E RatioN/A

Dividend YieldN/A

Beta1.13

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
XOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.50, XOMA has a potential upside of 35.9% from its current price of $21.70.
Amount of Analyst Coverage
XOMA has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
XOMA has received 408 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
XOMA has received 403 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
XOMA has received 50.31% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote “Outperform” if you believe XOMA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
XOMA does not currently pay a dividend.
Dividend Growth
XOMA does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, XOMA insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,008,822.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 9.89% of the stock of XOMA is held by insiders.
Percentage Held by Institutions
43.71% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for XOMA are expected to grow in the coming year, from ($1.60) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of XOMA is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of XOMA is -17.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
XOMA has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.13 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:XOMA

Previous Symbol

CUSIP98419J10

CIK791908

Webwww.xoma.com

Phone510-204-7200

Debt

Debt-to-Equity Ratio0.62

Current Ratio5.57

Quick Ratio5.57

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$18.37 million

Price / Sales13.01

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.03 per share

Price / Book4.31

Profitability

EPS (Most Recent Fiscal Year)($0.23)

Net Income$-1,980,000.00

Net Margins-102.32%

Return on Equity-34.27%

Return on Assets-12.84%

Miscellaneous

Employees11

Outstanding Shares11,015,000

Market Cap$239.03 million

Next Earnings Date8/4/2020 (Estimated)

OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA (NASDAQ:XOMA) Frequently Asked Questions

How has XOMA's stock been impacted by COVID-19 (Coronavirus)?

XOMA's stock was trading at $19.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XOMA stock has increased by 11.3% and is now trading at $21.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XOMA.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for XOMA.

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) issued its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.33. The biotechnology company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $3.40 million. XOMA had a negative net margin of 102.32% and a negative return on equity of 34.27%. View XOMA's earnings history.

What price target have analysts set for XOMA?

2 analysts have issued 12 month price objectives for XOMA's stock. Their forecasts range from $29.00 to $30.00. On average, they anticipate XOMA's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price. View analysts' price targets for XOMA.

Has XOMA been receiving favorable news coverage?

News stories about XOMA stock have been trending somewhat positive on Thursday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. XOMA earned a news impact score of 1.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutXOMA.

Who are some of XOMA's key competitors?

Some companies that are related to XOMA include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of XOMA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), TransEnterix (TRXC), Opko Health (OPK), Gilead Sciences (GILD), Uranium Energy (UEC), Ekso Bionics (EKSO) and NXP Semiconductors (NXPI).

Who are XOMA's key executives?

XOMA's management team includes the following people:

Mr. James R. Neal, CEO & Director (Age 63)
Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
Dr. Deepshikha Datta, Chief Bus. Officer

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (1.89%), BlackRock Inc. (1.78%), Geode Capital Management LLC (0.54%), Cadence Capital Management LLC (0.50%), EAM Investors LLC (0.36%) and Invesco Ltd. (0.29%). Company insiders that own XOMA stock include Bvf Partners L P/Il, James R Neal, Ness W Denman Van, Thomas M Burns and Value Fund L P Biotechnology. View institutional ownership trends for XOMA.

Which major investors are selling XOMA stock?

XOMA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Two Sigma Investments LP, Geode Capital Management LLC, BlackRock Inc., Alps Advisors Inc., First Manhattan Co., and EAM Investors LLC. Company insiders that have sold XOMA company stock in the last year include James R Neal, and Thomas M Burns. View insider buying and selling activity for XOMA.

Which major investors are buying XOMA stock?

XOMA stock was bought by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Invesco Ltd., Stonepine Capital Management LLC, Wells Fargo & Company MN, and Citigroup Inc.. Company insiders that have bought XOMA stock in the last two years include Bvf Partners L P/Il, James R Neal, and Value Fund L P Biotechnology. View insider buying and selling activity for XOMA.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $21.70.

How big of a company is XOMA?

XOMA has a market capitalization of $239.03 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe.

What is XOMA's official website?

The official website for XOMA is www.xoma.com.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff